Department of Defense Increases Development Contract With Cleveland BioLabs for CBLB502

BUFFALO, NY--(Marketwire - Jun 30, 2011) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it received a $1,531,034 increase (including option) in the development portion of the Company's existing contract, awarded on September 16, 2010, from the United States Department of Defense (DoD) Chemical Biological and Medical Systems (CBMS) Medical Identification and Treatment Systems (MITS) to fund additional development activities for CBLB502, a medical radiation countermeasure.